Long-term eff ects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes, et al.
Summary: Background Immunisation of patients with Alzheimer’s disease with full-length amyloid-β peptide (Aβ42) can clear amyloid plaques from the brain. Our aim was to assess the relation between Aβ42 immune response, degree of plaque removal, and long-term clinical outcomes.
One claim made in the paper is that patients "with virtually complete plaque removal, had severe end stage dementia." John would like us to discuss this claim, and determine if really supported by the data. If yes, how? If not, what else might the data mean?
Look forward to a wonderful discussion. Please make sure to make a zoom.us account to join the discussion.
The paper is attached!
Thanks.
Nina
--
--
You received this message because you are subscribed to the Google
Groups "BioCurious" group.
To post to this group, send email to biocu...@googlegroups.com
To unsubscribe from this group, send email to
biocurious+...@googlegroups.com
For more options, visit this group at
http://groups.google.com/group/biocurious?hl=en
---
You received this message because you are subscribed to the Google Groups "BioCurious" group.
To unsubscribe from this group and stop receiving emails from it, send an email to biocurious+...@googlegroups.com.
For more options, visit https://groups.google.com/groups/opt_out.